Literature DB >> 27855539

Mouse P2Y4 Nucleotide Receptor Is a Negative Regulator of Cardiac Adipose-Derived Stem Cell Differentiation and Cardiac Fat Formation.

Anne Lemaire1, Marion Vanorlé1, Michael Horckmans1, Larissa di Pietrantonio1, Sophie Clouet1, Bernard Robaye2, Jean-Marie Boeynaems1,3, Didier Communi1.   

Abstract

Cardiac adipose tissue-derived stem cells (cASCs) have the ability to differentiate into multiple cell lineages giving them a high potential for use in regenerative medicine. Cardiac fat tissue still raises many unsolved questions related to its formation and features. P2Y nucleotide receptors have already been described as regulators of differentiation of bone-marrow derived stem cells, but remain poorly investigated in cASCs. We defined, in this study, the P2Y4 nucleotide receptor as a negative regulator of cardiac fat formation and cASC adipogenic differentiation. Higher expression of P2Y4 receptor in cardiac fat tissue was observed compared to other adipose tissues. P2Y4-null mice displayed a higher mass of cardiac adipose tissue specifically. We therefore examined the role of P2Y4 receptor in cASC adipogenic differentiation. An inhibitory effect of uridine 5'-triphosphate (UTP), ligand of P2Y4, was observed on the maturation state of differentiated cASCs, and on the expression of adipogenesis-linked genes and adiponectin, a cardioprotective adipokine. Higher adiponectin secretion by P2Y4-null adipocytes could be linked with cardioprotection previously observed in the heart of P2Y4-null ischemic mice. We realized here left anterior descending artery ligation on simple and double-knockout mice for P2Y4 and adiponectin. No cardioprotective effect of P2Y4 loss was observed in the absence of adiponectin secretion. In addition, P2Y4 loss was correlated with higher expression of UCP-1 (uncoupling protein-1) and CD137, two markers of brown/beige cardiac adipocytes. Our data highlight the P2Y4 receptor as an inhibitor of cardiac fat formation and cASC adipogenic differentiation, and as a potential therapeutic target in the regulation of cardioprotective function of cardiac fat.

Entities:  

Keywords:  P2Y receptors; adipogenesis; adipose stem cells; cardiac; differentiation; extracellular nucleotides

Mesh:

Substances:

Year:  2016        PMID: 27855539     DOI: 10.1089/scd.2016.0166

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  9 in total

Review 1.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

Review 2.  Adipocyte purinergic receptors activated by uracil nucleotides as obesity and type 2 diabetes targets.

Authors:  Shanu Jain; Kenneth A Jacobson
Journal:  Curr Opin Pharmacol       Date:  2022-02-26       Impact factor: 5.547

3.  UTP Regulates the Cardioprotective Action of Transplanted Stem Cells Derived From Mouse Cardiac Adipose Tissue.

Authors:  Esteban Diaz Villamil; Lucas De Roeck; Marion Vanorlé; Didier Communi
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

Review 4.  Purinergic signaling in diabetes and metabolism.

Authors:  Shanu Jain; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2020-12-25       Impact factor: 5.858

Review 5.  Update of P2Y receptor pharmacology: IUPHAR Review 27.

Authors:  Kenneth A Jacobson; Esmerilda G Delicado; Christian Gachet; Charles Kennedy; Ivar von Kügelgen; Beibei Li; M Teresa Miras-Portugal; Ivana Novak; Torsten Schöneberg; Raquel Perez-Sen; Doreen Thor; Beili Wu; Zhenlin Yang; Christa E Müller
Journal:  Br J Pharmacol       Date:  2020-04-06       Impact factor: 9.473

6.  Central role of PD-L1 in cardioprotection resulting from P2Y4 nucleotide receptor loss.

Authors:  Michael Horckmans; Esteban Diaz Villamil; Lucas De Roeck; Didier Communi
Journal:  Front Immunol       Date:  2022-09-28       Impact factor: 8.786

7.  UTP is a regulator of in vitro and in vivo angiogenic properties of cardiac adipose-derived stem cells.

Authors:  Michael Horckmans; Didier Communi; Marion Vanorlé; Anne Lemaire; Larissa di Pietrantonio
Journal:  Purinergic Signal       Date:  2021-08-05       Impact factor: 3.765

Review 8.  Purinergic Receptors in Adipose Tissue As Potential Targets in Metabolic Disorders.

Authors:  Marco Tozzi; Ivana Novak
Journal:  Front Pharmacol       Date:  2017-11-24       Impact factor: 5.810

Review 9.  The involvement of purinergic signalling in obesity.

Authors:  Geoffrey Burnstock; Daniela Gentile
Journal:  Purinergic Signal       Date:  2018-04-04       Impact factor: 3.765

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.